BSH 2019 | Follow-up of the ALLR3 trial: pediatric late bone marrow relapse & lessons learned
The ALLR3 trial (NCT00967057) was an open-label, randomized clinical trial that investigated the outcomes of pediatric B-cell precursor acute lymphoblastic leukaemia (ALL) who had late bone marrow relapses and were treated with combination chemotherapy. Here, Vaskar Saha, MBBS, DCH, MD, FRCP, FRCPath, PhD, University of Manchester, Manchester, UK, discusses the follow-up on the trial. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.
Get great new content delivered to your inboxSign up